RxDoctor Payments Data

Liberty Neoh, NP

Nurse Practitioner · Booneville, ARNPI 1700395225

Payments from drug & device makers

$3,455in general payments, 2019–2025

Across 160 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$697
  • Xeris Pharmaceuticals, Inc.$326
  • Lilly USA, LLC$318
  • Sanofi-aventis U.S. LLC$295
  • Abbott$280
  • Novo Nordisk$276
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,455100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,455 in reported general payments places this provider in the 85th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$61,097
Medicare patients
435
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$106,219
JardianceEmpagliflozin42$36,676
TrulicityDulaglutide19$24,096
FarxigaDapagliflozin Propanediol16$21,585
Tresiba Flextouch U-200Insulin Degludec23$20,376
MounjaroTirzepatide15$16,136
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$8,381
Novolog FlexpenInsulin Aspart33$5,405
NovologInsulin Aspart19$4,053
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,242
Tirosint-SolLevothyroxine Sodium18$2,558
Calcium Acetate16$716
Levothyroxine Sodium52$615
Hydralazine Hcl48$581
Losartan Potassium86$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$276$110,271110 claims
Lilly USA, LLCTrulicity, Mounjaro$318$40,23234 claims
Boehringer IngelheimJardiance$149$36,67642 claims
AstraZenecaFarxiga$126$21,58516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Booneville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →